Abstract

BackgroundLarge scale randomized studies are underway to assess whether compared to placebo, each XO-inhibitor, allopurinol or febuxostat, can prevent renal function loss. This evidence is needed and will confirm their...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call